Gilead Sciences, Inc. today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% (30 out of 37) of participants with primary biliary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback